Clinical trials
catalyst calendar across sponsors →Studies where TEVA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 3 with posted results
Held by 17 tracked-famous managers (GLENVIEW CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, DME Capital Management, LP, Bridgewater Associates, LP, Point72 Asset Management, L.P., +12 more) · FINRA short interest 5.7 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 4 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the DiseaseNCT00745615results2019-03-27Double-Blind Extension Period: Number of Participants With Adverse Events (AEs)Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose. | Drug: Laquinimod, Placebo | Relapsing Remitting Multiple Sclerosis | 257 | 2017-07-23actual | 2019-03-27 |
| A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient ChildrenNCT02092077Height velocity (HV)Randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business decision | Drug: TV-1106, somatropin | Growth Hormone-Deficiency | 65 | 2016-04-30actual | 2021-11-09 |
| TL011 in Severe, Active Rheumatoid Arthritis PatientsNCT01123070results2021-10-04Area Under the Plasma Concentration Versus Time Curve [AUC(0-t)] in Part BRandomized · Triple-masked · Treatment | Phase 1 | Completed | Biological: TL011, anti CD20, for the treatment of rheumatoid arthritis, MabThera infusions | Rheumatoid Arthritis | 54 | 2012-04-23actual | 2021-10-04 |
| Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)NCT00326625results2021-10-20Slope of Change From Baseline in the ALS Functional Rating Scale (ALSFRS-R)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: 40 mg glatiramer acetate, Placebo | Amyotrophic Lateral Sclerosis | 366 | 2008-06-17actual | 2022-08-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19